Moderna provided updates on key elements of its pipeline, including a next-generation COVID-19 vaccine, an RSV vaccine, a new ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)Updates 2025 expected revenue range to $1.5 to 2.5 billionExpects to ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) ...